Scarica l'app Stockscreener
314.00
0.09%
-0.28
Dopo l'orario di chiusura:
314.38
0.38
+0.12%
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
3,846 Shares in Praxis Precision Medicines, Inc. $PRAX Acquired by Coastal Bridge Advisors LLC - MarketBeat
Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Exploring a 63% Upside in the Biotech Sector - DirectorsTalk Interviews
PRAX: HC Wainwright & Co. Raises Price Target and Maintains Buy Rating | PRAX Stock News - GuruFocus
H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 - Investing.com Nigeria
Praxis Precision Medicines plans two NDA submissions by mid-February - Investing.com Nigeria
Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 - Investing.com Canada
Is Praxis Precision Medicines Inc part of any major indexTrade Analysis Report & Daily Market Momentum Tracking - baoquankhu1.vn
Piper Sandler Raises PRAX Price Target to $1,200, Maintains Overweight Rating | PRAX Stock News - GuruFocus
Discipline and Rules-Based Execution in PRAX Response - Stock Traders Daily
Should Praxis Precision Medicines’ (PRAX) New Clinical Strategy Chief Reshape Its Long-Term Epilepsy Investment Story? - Sahm
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $450 - 富途牛牛
Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock - Investing.com
PRAX Stock Price, Forecast & Analysis | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - Chartmill
SG Americas Securities LLC Invests $715,000 in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis speeds up R&D plans for seizure therapy after FDA feedback - MSN
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Nisa Investment Advisors LLC Has $378,000 Stake in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines stock hits 52-week high at $318.24 By Investing.com - Investing.com Nigeria
Praxis Precision Medicines (PRAX) Valuation As NDA Plans And New Clinical Leadership Point To Commercial Transition - Sahm
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 12-Month HighWhat's Next? - MarketBeat
Praxis Precision Medicines stock hits 52-week high at $318.24 - Investing.com
Behavioral Patterns of PRAX and Institutional Flows - Stock Traders Daily
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus - Insider Monkey
Aug PreEarnings: Can Praxis Precision Medicines Inc outperform in the next rallyPortfolio Value Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Is Praxis Precision Medicines (PRAX) Price Missing The Story After A 326% One-Year Surge? - Sahm
Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom - TechStock²
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 7%Here's Why - MarketBeat
Praxis Precision Medicines (PRAX) Price Target Increased by 14.92% to 471.78 - Nasdaq
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy - PharmiWeb.com
Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy - citybiz
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - Investing News Network
Buyout Rumor: Can Praxis Precision Medicines Inc deliver consistent dividendsJuly 2025 Trends & Smart Money Movement Alerts - baoquankhu1.vn
Praxis Precision Medicines Appoints Orrin Devinsky as Head of Clinical Strategy - marketscreener.com
US Biotech Share Sales Deliver Biggest First Week Since 2021 - Bloomberg.com
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.1%Here's Why - MarketBeat
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress - Investing News Network
Praxis Precision Medicines (PRAX) Sets Ambitious Targets for 202 - GuruFocus
PRAX: Wedbush Raises Price Target Despite "Underperform" Rating - GuruFocus
Wedbush Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Needham analyst keeps a buy rating on Praxis Precision Medicines, Inc. (PRAX) - MSN
Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance
20 Best Performing Stocks in 2025 - Insider Monkey
Will Praxis Precision Medicines Inc. stock see PE expansionPerformance Line Overview & quick comparison of popular models - ulpravda.ru
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):